Eledon Pharmaceuticals (ELDN) Stock Forecast & Price Target

Eledon Pharmaceuticals Inc. demonstrates a promising outlook due to the encouraging results related to its compound tegoprubart, which shows potential to improve graft survival and kidney function in transplant patients compared to standard treatments. The Phase 2 BESTOW trial results indicate that tegoprubart offers favorable safety and tolerability profiles, with significantly reduced toxicities compared to tacrolimus, a commonly used immunosuppressant. Moreover, the stabilization of kidney function, maintaining an estimated glomerular filtration rate of approximately 68 mL/min/1.73m² over 12 months, positions tegoprubart favorably against historical benchmarks, suggesting significant therapeutic potential in the transplantation and autoimmune disease markets.

Eledon Pharmaceuticals Inc reported a net loss of $17.5 million for Q3 2025, a significant decline from the net income of $77.0 million in Q3 2024, which was bolstered by a non-cash gain. The company's operating expenses decreased to $19.1 million, primarily from lower research and development costs; however, ongoing financial strain highlighted constraints in achieving substantial sales potential. Additionally, significant risks related to the clinical development and commercialization of tegoprubart, including potential failures in trials, regulatory approval, and market competition, contribute to a negative outlook for the company's financial stability and future performance.